NRX Pharmaceuticals Inc
NRXP
Company Profile
Business description
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Contact
1201 Orange Street
Suite 600
WilmingtonDE19801
USAT: +1 484 254-6134
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
Stocks News & Analysis
stocks
More US tech stocks look cheap as the market rotates
Meanwhile, value-leaning areas of the market, including industrials and energy stocks, are moving out of undervalued territory.
stocks
Earnings Losers: GYG, DMP & LLC slump on souring market sentiment
The results that fell short of market expectations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,412.00 | 62.00 | 0.66% |
| CAC 40 | 8,580.75 | 40.18 | -0.47% |
| DAX 40 | 25,284.26 | 4.76 | -0.02% |
| Dow JONES (US) | 48,977.92 | 521.28 | -1.05% |
| FTSE 100 | 10,910.55 | 63.85 | 0.59% |
| HKSE | 26,209.91 | 420.63 | -1.58% |
| NASDAQ | 22,668.21 | 210.17 | -0.92% |
| Nikkei 225 | 58,126.46 | 723.81 | -1.23% |
| NZX 50 Index | 13,656.65 | 66.32 | -0.48% |
| S&P 500 | 6,878.88 | 29.98 | -0.43% |
| S&P/ASX 200 | 9,181.30 | 61.60 | 0.68% |
| SSE Composite Index | 4,163.01 | 0.13 | 0.00% |